NY-AB-INBEV
30.5.2024 07:01:28 CEST | Business Wire | Press release
Today, Danone has joined AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), The Coca-Cola Company, Colgate-Palmolive Company, and Unilever as the fifth partner in the 100+ Accelerator, the groundbreaking program dedicated to pioneering sustainable innovation across global supply chains.
Launched in 2018 by AB InBev, the 100+ Accelerator has rapidly become a cornerstone initiative for catalyzing environmental stewardship and sustainable business practices through global collaboration and groundbreaking solutions in critical areas such as water stewardship, circular economy, sustainable agriculture, and climate action. In 2021, the 100+ Accelerator welcomed its first three partners to expand this unique approach to innovation and to further establish the value proposition of the program’s brand and mission. To date, it has accelerated 148 companies in 38 countries.
“Sustainability is core to our business strategy and fulfills our purpose of dreaming big to create a future with more cheers,” said Ingrid De Ryck, Chief Sustainability Officer of AB InBev. “In the 5 years since its launch, the 100+ Accelerator has helped us identify and scale solutions to business challenges, advance our 2025 sustainability goals and improve resilience across supply chains. We welcome Danone as a strategic partner in the 100+ Accelerator and are excited to continue developing the program’s impact through industry collaboration.”
“Our combined global reach will undoubtedly propel the 100+ Accelerator to new heights, driving broader adoption of sustainable innovations that will benefit our planet, our communities and our future.” Vikram Agarwal, Chief Operations Officer, Danone, also expressed his enthusiasm for the partnership: "This collaboration with 100+ Accelerator is yet another milestone in Danone's sustainability journey and is a direct result of our Partner For Growth program. It shows our commitment to working with all partners across our ecosystem to leverage our respective strengths to create shared value. With 100+ Accelerator, start-ups will be able to harness our internal resources to scale-up innovation that will deliver tangible environmental benefits across the value chain.”
Isabelle Esser, Danone Chief Research, Innovation, Quality and Food Safety Officer added, “We are proud to join the 100+ Accelerator program, which is fully aligned with our ambition to drive sustainable innovation for the future of our planet and our consumers. At Danone, we believe that strong partnerships are essential to help us stay one step ahead of global challenges, while continuing to honor our mission of shaping the food of tomorrow.”
The program's effectiveness is evidenced by its impact:
- Implementation of a range of technologies that help improve water efficiency including nanotechnology, electrochemistry and spectroscopy.
- Enhanced traceability and support systems for smallholder farmers, endeavoring to improve livelihoods and agricultural sustainability across continents.
- Fleet optimization including EV retrofitting, hydrogen co-fueling, aerodynamic solutions and hybrid charging.
- New cooling applications including thermodynamic coatings and magnetic refrigeration.
- Bio-based, compostable packaging alternatives or additives from banana fiber, spent grain, corn husk, bacterial nano-cellulose among others.
Applications for the sixth cohort of the accelerator will open on May 30. Forward-thinking entrepreneurs are invited to apply at www.100accelerator.com.
With the collective capabilities of AB InBev, The Coca-Cola Company, Colgate-Palmolive, Danone, and Unilever, the 100+ Accelerator will continue to scale innovative solutions to create a more sustainable world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529855383/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom